



Anadis and Tatura Milk Industries collaborate to take on export markets

Friday 19 September 2008

In light of recent successes in negotiating sale of Anadis based products into markets in USA and Asia, Anadis and Tatura Milk Industries (TMI) are co-operating to increase the volume of colostrums product leaving Australia.

TMI, a large Goulburn Valley based dairy company, is a major shareholder in Anadis Limited and is assisting the increased commercialisation push with manufacturing systems, market development input and export logistics management. As regulatory and distribution hurdles are being overcome, exports markets are expected in the short term in Asia, USA and Europe. Anadis and TMI are also combining to develop a range of high volume products for TMI's major clients in Asia.

"These new orders will consume our current product stockpiles quickly and they need to be replaced to meet demand. Our alliance with TMI will assist us grow our commercialisation effort into profit." said Dr Zeil Rosenberg, Anadis CEO.

Aidan Coleman, CEO of Tatura Milk Industries, says – "As a major shareholder of Anadis and as a specialised dairy ingredients company we will assist Anadis in its growth phase. I am sure there will be an increasing collaboration between the two companies and I look forward to further commercial success".

For further information contact:

Dr. Zeil Rosenberg - CEO
Email: zeil@anadis.com
Tel: +1 646 402 5289

Dr. Oren Fuerst- VP, Business Development
Email: oren@anadis.com
Tel +1 646 259 3321

Gran Rawlin – VP, Research and Development
Email: grant@anadis.com
Tel: +61 3 9018 4880

AUSTRALIA
4 Capital Link Drive,
Campbellfield, VICTORIA, 3061
Tel (61) 3 9358 6388 Fax (61) 3 9358 6399

USA
The Empire State Building
350 Fifth Avenue 59th Floor
New York, N.Y. 10118
Tel 646 402 5289 Fax 646 390 3238



Arie Nudel- Investor Relations
Email: arie@anadis.com
Tel: +61 3 9014 4880

[Anadis Limited](#) ([ASX: ANX](#); OTC: ANDIY) is a biopharmaceutical company focused on antigen-primed, dairy-derived health products. Anadis' proprietary technology enables it to rapidly develop polyclonal antibody and other proteins-based solutions to a range of important diseases. The all-natural colostrum-derived platform, its high safety profile when administered orally and the proprietary methods of manufacturing, allows for short time-frame from bench to market with high manufacturing scalability.

AUSTRALIA

4 Capital Link Drive,
Campbellfield, VICTORIA, 3061
Tel (61) 3 9358 6388 Fax (61) 3 9358 6399

USA

The Empire State Building
350 Fifth Avenue 59th Floor
New York, N.Y. 10118
Tel 646 402 5289 Fax 646 390 3238